Opulence Capital has announced a landmark initiative to construct Saudi Arabia’s first Co-Polymer 2A manufacturing facility, developed in collaboration with an elite multinational coalition of industry leaders. This state-of-the-art facility will not only position Saudi Arabia as a global center for high-performance polymers but also create unprecedented opportunities for collaboration with major pharmaceutical players and regional government agencies.
This ambitious project, a milestone in advanced materials manufacturing, leverages the strengths of Opulence Capital and its international partners, including a renowned German engineering and manufacturing leader in high-precision polymer applications. Together, this coalition brings a wealth of expertise and cutting-edge technology to Saudi Arabia, aiming to produce Co-Polymer 2A at a scale and quality that meets the rigorous standards of the world’s largest pharmaceutical and medical device companies.
Left to right; S. Ivett Guajardo, Director of Investor Relations MENA Opulence Capital; Dr. Tawfiq Al Swailem, Chairman of the Gulf Bureau of Economic Development and Saudi Ministry of Investment Advisor; Sukru Muammer Oner, Board Member Opulence Capital Caption: Opulence Capital multinational coalition engages with Saudi Ministry of Investment on key project for diversification of Saudi economy with key advanced technology manufacturing plant for Co Polymer 2a syringes. Anticipated involvement from the Saudi Industrial Development Fund and National Procurement Office of Saudi Arabia alongside the Ministry of Health and Health Holding Company.
“Through this coalition, we’re creating a foundation for Saudi Arabia to lead in high-performance polymer production, a sector critical for the future of healthcare and technology,” said S. Ivett Guajardo, Director of Investor Relations, MENA at Opulence Capital. “This facility not only exemplifies our commitment to Vision 2030 but also serves as a platform for collaboration with global pharma giants and local government agencies, establishing Saudi Arabia as a leading supplier of medical-grade polymers to the world.”
The new Co-Polymer 2A factory will prioritize close collaboration with major pharmaceutical companies across the Middle East, Africa, and Asia, offering them a local and reliable source of essential polymer materials for packaging, drug delivery, and medical device applications. This facility is expected to meet the needs of a growing pharmaceutical market by providing a more resilient, cost-effective, and regionally aligned supply chain.
Beyond the healthcare sector, the project aligns with Saudi Arabia’s Vision 2030, actively engaging government bodies and economic development authorities to foster job creation, local supplier integration, and sustainable economic impact. With advanced environmental protocols and cutting-edge technology, the facility will reflect the coalition’s commitment to sustainable manufacturing, aligning with the Kingdom’s goals for responsible industrial growth.
The establishment of this facility sets a new benchmark for innovation and strategic partnership in the region. By uniting Opulence Capital’s regional presence with the expertise of global leaders in polymer production, this coalition will drive transformative growth across multiple sectors, from healthcare to advanced manufacturing.
Media Contact
Company Name: Opulence Capital
Contact Person: Adam Gorland
Email: Send Email
City: Riyadh
Country: Saudi Arabia
Website: https://opulence.net
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Opulence Capital to Establish Saudi Arabia’s Premier Co-Polymer 2A Facility in Alliance with Multinational Coalition and Strategic Regional Partners